Tag - BRAFTOVI (encorafenib)

Combination Therapy BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the Treatment of BRAF-mutant Melanoma, Available for Order at Biologics, Inc.

July 4, 2018

👁 1287 views

Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Array BioPharma, Inc. to be...

Tag - BRAFTOVI (encorafenib)

Combination Therapy BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the Treatment of BRAF-mutant Melanoma, Available for Order at Biologics, Inc.

Press Releases

HIE market to hit $3.40B by 2031 (MarketsandMarkets).

NeoGenomics Integrates Cancer Testing with Epic EHR

Timeless Medical Systems® appoints Mike Antonelli as VP of Technology to drive next-generation platform innovation

Luma acquires Tonic to support 1,000+ health systems and 100M patients

Newsletter

Research Papers

Mount Sinai Health System to Deploy Microsoft Dragon Copilot

Ambient AI saves time, eases burnout, and strengthens patient connections

Reactions to EHR-Based Clinical Study Invitations

IDC MarketScape evaluates U.S. EHR vendors